Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 3
1990 1
1993 2
1994 4
1995 2
1996 4
1997 1
1998 7
1999 1
2000 3
2001 10
2002 10
2003 11
2004 12
2005 11
2006 6
2007 12
2008 18
2009 11
2010 19
2011 18
2012 14
2013 17
2014 12
2015 7
2016 9
2017 2
2018 7
2019 6
2020 4
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Niacin extended-release/simvastatin.
Sanford M, Curran MP. Sanford M, et al. Drugs. 2008;68(16):2373-86. doi: 10.2165/0003495-200868160-00008. Drugs. 2008. PMID: 18973399 Review.
Niacin extended-release (ER)/simvastatin is a once-daily, fixed-dose combination of the HMG-CoA reductase inhibitor simvastatin and an ER formulation of niacin (a B-complex vitamin). In healthy volunteers who were given niacin ER/simvastatin …
Niacin extended-release (ER)/simvastatin is a once-daily, fixed-dose combination of the HMG-CoA reductase inhibitor simvast …
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. AIM-HIGH Investigators, et al. N Engl J Med. 2011 Dec 15;365(24):2255-67. doi: 10.1056/NEJMoa1107579. Epub 2011 Nov 15. N Engl J Med. 2011. PMID: 22085343 Free article. Clinical Trial.
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvasta …
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low …
Safety of niacin and simvastatin combination therapy.
Bays H. Bays H. Am J Cardiol. 2008 Apr 17;101(8A):3B-8B. doi: 10.1016/j.amjcard.2008.02.026. Am J Cardiol. 2008. PMID: 18375239 Review.
Niacin's major adverse experience (AE) is flushing. Niacin may also increase glucose levels, liver enzymes, and uric acid levels and cause other AEs that may have clinical relevance in selected patients. ...Equally important is ensuring that the combination o …
Niacin's major adverse experience (AE) is flushing. Niacin may also increase glucose levels, liver enzymes, and uric ac …
Lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-152. Med Lett Drugs Ther. 2022. PMID: 36094548 No abstract available.
In Vitro Targeted Delivery of Simvastatin and Niacin to Macrophages Using Mannan-Grafted Magnetite Nanoparticles.
Rastegari B, Ghamar Talepoor A, Khosropanah S, Doroudchi M. Rastegari B, et al. ACS Omega. 2023 Dec 18;9(1):658-674. doi: 10.1021/acsomega.3c06389. eCollection 2024 Jan 9. ACS Omega. 2023. PMID: 38222576 Free PMC article.
The low dosage of simvastatin decreased both IL-6 and ARG1 expressions, while niacin and combined simvastatin/niacin increased the level of ARG1 expression significantly. Toxicity evaluations on human umbilical vein endothelial cells and murine liver c …
The low dosage of simvastatin decreased both IL-6 and ARG1 expressions, while niacin and combined simvastatin/niacin …
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Robinson JG. Robinson JG. Vasc Health Risk Manag. 2009;5(1):31-43. doi: 10.2147/vhrm.s3190. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436666 Free PMC article. Review.
ER niacin 1000 mg combined with simvastatin 20 mg reduced LDL-C by 6%, non-HDL-C by 7%, and triglycerides by 13%, and raised HDL-C by 11% compared to simvastatin 20 mg alone. ...However, drop-out rates were high in both the simvastatin and ER niacin …
ER niacin 1000 mg combined with simvastatin 20 mg reduced LDL-C by 6%, non-HDL-C by 7%, and triglycerides by 13%, and raised H …
Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
Lauring B, Dishy V, De Kam PJ, Crumley T, Wenning L, Liu F, Sisk C, Wagner J, Lai E. Lauring B, et al. Am J Ther. 2015 Sep-Oct;22(5):367-76. doi: 10.1097/MJT.0000000000000051. Am J Ther. 2015. PMID: 24832384 Clinical Trial.
Study 1 used single doses of extended-release niacin and simvastatin; study 2 used multiple-dose coadministration of extended-release niacin/laropiprant and simvastatin in healthy subjects; and study 3 used single doses of both extended-release niac …
Study 1 used single doses of extended-release niacin and simvastatin; study 2 used multiple-dose coadministration of extended- …
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Brown BG, et al. N Engl J Med. 2001 Nov 29;345(22):1583-92. doi: 10.1056/NEJMoa011090. N Engl J Med. 2001. PMID: 11757504 Free article. Clinical Trial.
METHODS: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin …
METHODS: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol leve …
Lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 11;61(1565):17-24. Med Lett Drugs Ther. 2019. PMID: 30845106 No abstract available.
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y. Ballantyne C, et al. J Clin Lipidol. 2012 May-Jun;6(3):235-43. doi: 10.1016/j.jacl.2011.11.004. Epub 2011 Dec 3. J Clin Lipidol. 2012. PMID: 22658147 Clinical Trial.
BACKGROUND: The use of extended-release niacin and the prostaglandin D2 receptor antagonist laropiprant (ERN/LRPT) reduces niacin-induced flushing in patients while preserving its lipid-modifying effects. OBJECTIVE: This predefined exploratory analysis examined the …
BACKGROUND: The use of extended-release niacin and the prostaglandin D2 receptor antagonist laropiprant (ERN/LRPT) reduces niacin …
235 results